PXMD Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
PaxMedica, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.095 |
| 52 Week High | US$1.19 |
| 52 Week Low | US$0.055 |
| Beta | -0.61 |
| 11 Month Change | -4.52% |
| 3 Month Change | -55.80% |
| 1 Year Change | -89.44% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.89% |
Recent News & Updates
Shareholder Returns
| PXMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.5% | 2.8% | 1.0% |
| 1Y | -89.4% | 13.3% | 31.4% |
Return vs Industry: PXMD underperformed the US Pharmaceuticals industry which returned 13.1% over the past year.
Return vs Market: PXMD underperformed the US Market which returned 30.7% over the past year.
Price Volatility
| PXMD volatility | |
|---|---|
| PXMD Average Weekly Movement | 43.9% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PXMD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PXMD's weekly volatility has increased from 31% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 7 | Howard Weisman | www.paxmedica.com |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT.
PaxMedica, Inc. Fundamentals Summary
| PXMD fundamental statistics | |
|---|---|
| Market cap | US$1.10m |
| Earnings (TTM) | -US$17.66m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PXMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$17.66m |
| Earnings | -US$17.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PXMD perform over the long term?
See historical performance and comparison